Victory Capital Management Inc. Acquires 10,011 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Victory Capital Management Inc. lifted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 23.3% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 53,060 shares of the medical instruments supplier’s stock after acquiring an additional 10,011 shares during the quarter. Victory Capital Management Inc.’s holdings in LeMaitre Vascular were worth $4,929,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of LMAT. NBC Securities Inc. lifted its position in shares of LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 183 shares in the last quarter. GAMMA Investing LLC lifted its holdings in LeMaitre Vascular by 57.0% during the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after purchasing an additional 199 shares in the last quarter. West Oak Capital LLC purchased a new stake in LeMaitre Vascular during the 2nd quarter worth about $58,000. USA Financial Formulas purchased a new position in LeMaitre Vascular during the 3rd quarter valued at about $60,000. Finally, nVerses Capital LLC increased its position in shares of LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after buying an additional 200 shares during the period. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Trading Up 2.0 %

LMAT opened at $107.97 on Friday. The stock has a market capitalization of $2.43 billion, a P/E ratio of 57.85, a PEG ratio of 2.54 and a beta of 0.89. The stock has a 50-day moving average price of $93.48 and a 200-day moving average price of $86.61. LeMaitre Vascular, Inc. has a 12-month low of $51.70 and a 12-month high of $108.09.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. The firm had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company’s revenue was up 15.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.33 EPS. On average, equities research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st will be given a dividend of $0.16 per share. The ex-dividend date is Thursday, November 21st. This represents a $0.64 annualized dividend and a dividend yield of 0.59%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.97%.

Insider Activity

In other news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now directly owns 2,278 shares in the company, valued at approximately $231,148.66. This represents a 62.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on LMAT. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target for the company. Barrington Research increased their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Oppenheimer restated an “outperform” rating and issued a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Finally, JMP Securities lifted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, LeMaitre Vascular presently has an average rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.